CA2961978C - Quinoline carboxamides for use in the treatment of multiple myeloma - Google Patents

Quinoline carboxamides for use in the treatment of multiple myeloma Download PDF

Info

Publication number
CA2961978C
CA2961978C CA2961978A CA2961978A CA2961978C CA 2961978 C CA2961978 C CA 2961978C CA 2961978 A CA2961978 A CA 2961978A CA 2961978 A CA2961978 A CA 2961978A CA 2961978 C CA2961978 C CA 2961978C
Authority
CA
Canada
Prior art keywords
compound
chloro
fluoro
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2961978A
Other languages
English (en)
French (fr)
Other versions
CA2961978A1 (en
Inventor
David LIBERG
Anders Olsson
Dmitry Gabrilovich
Yuliya NEFEDOVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Publication of CA2961978A1 publication Critical patent/CA2961978A1/en
Application granted granted Critical
Publication of CA2961978C publication Critical patent/CA2961978C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2961978A 2014-09-23 2015-09-18 Quinoline carboxamides for use in the treatment of multiple myeloma Active CA2961978C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14185892.8 2014-09-23
EP14185892 2014-09-23
PCT/EP2015/071391 WO2016042112A1 (en) 2014-09-23 2015-09-18 Quinoline carboxamides for use in the treatment of multiple myeloma

Publications (2)

Publication Number Publication Date
CA2961978A1 CA2961978A1 (en) 2016-03-24
CA2961978C true CA2961978C (en) 2023-03-14

Family

ID=51660309

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2961978A Active CA2961978C (en) 2014-09-23 2015-09-18 Quinoline carboxamides for use in the treatment of multiple myeloma

Country Status (15)

Country Link
US (2) US9956212B2 (en:Method)
EP (1) EP3041472B1 (en:Method)
JP (1) JP6647287B2 (en:Method)
KR (1) KR102533033B1 (en:Method)
CN (1) CN107108510B (en:Method)
AU (1) AU2015316824B2 (en:Method)
CA (1) CA2961978C (en:Method)
EA (1) EA030948B1 (en:Method)
ES (1) ES2631194T3 (en:Method)
IL (1) IL251043B (en:Method)
MX (1) MX366837B (en:Method)
NZ (1) NZ730816A (en:Method)
PL (1) PL3041472T3 (en:Method)
WO (1) WO2016042112A1 (en:Method)
ZA (1) ZA201702377B (en:Method)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108510B (zh) * 2014-09-23 2020-10-23 活跃生物技术有限公司 用于治疗多发性骨髓瘤的喹啉甲酰胺
KR20220149579A (ko) * 2020-03-03 2022-11-08 액티브 바이오테크 에이비 조합 요법에 사용하기 위한 타스퀴니모드 또는 이의 약학적으로 허용가능한 염
PL4185292T3 (pl) 2020-07-23 2025-10-13 Erasmus University Medical Center Rotterdam Białka s100 jako nowe cele terapeutyczne w przypadku nowotworów mieloproliferacyjnych
MX2023008016A (es) 2021-01-18 2023-07-13 Active Biotech Ab Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico.
PL4346773T3 (pl) 2021-05-25 2025-11-03 Active Biotech Ab Duża liczba cząstek taskwinimodu i ich zastosowanie
JP2024524158A (ja) 2021-07-02 2024-07-05 アクティブ バイオテック エイビー タスキニモドを含有する医薬製品および前記製品の純度を評価する方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
PL199781B1 (pl) * 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US9469876B2 (en) * 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
EA021171B1 (ru) 2010-07-09 2015-04-30 Эктив Байотек Аб Способ получения хинолин-3-карбоксамидов
US20140148350A1 (en) * 2010-08-18 2014-05-29 David Spetzler Circulating biomarkers for disease
WO2012034543A1 (es) 2010-09-13 2012-03-22 Universidad De Costa Rica Conector estructural para bambú
FR2967353B1 (fr) * 2010-11-16 2013-08-16 Centre Nat Rech Scient Derives de quinolinone
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
CN107108510B (zh) * 2014-09-23 2020-10-23 活跃生物技术有限公司 用于治疗多发性骨髓瘤的喹啉甲酰胺

Also Published As

Publication number Publication date
ES2631194T3 (es) 2017-08-29
US10314836B2 (en) 2019-06-11
US9956212B2 (en) 2018-05-01
ZA201702377B (en) 2018-08-29
JP2017528473A (ja) 2017-09-28
CA2961978A1 (en) 2016-03-24
EA030948B1 (ru) 2018-10-31
AU2015316824B2 (en) 2020-10-29
AU2015316824A1 (en) 2017-04-27
CN107108510A (zh) 2017-08-29
MX366837B (es) 2019-07-26
KR102533033B1 (ko) 2023-05-15
CN107108510B (zh) 2020-10-23
EA201790687A1 (ru) 2017-08-31
WO2016042112A1 (en) 2016-03-24
BR112017004947A2 (pt) 2017-12-05
PL3041472T3 (pl) 2017-08-31
NZ730816A (en) 2022-01-28
KR20170052691A (ko) 2017-05-12
MX2017003294A (es) 2017-06-23
JP6647287B2 (ja) 2020-02-14
IL251043B (en) 2020-02-27
IL251043A0 (en) 2017-04-30
US20180228794A1 (en) 2018-08-16
US20170273967A1 (en) 2017-09-28
EP3041472B1 (en) 2017-02-01
EP3041472A1 (en) 2016-07-13

Similar Documents

Publication Publication Date Title
US10314836B2 (en) Quinoline carboxamides for use in the treatment of multiple myeloma
CA2967112C (en) Quinoline carboxamides for use in the treatment of leukemia
JP2006070032A (ja) 抗血管形成薬剤組成物
JP2017534652A5 (en:Method)
HK1226643A1 (en) Quinoline carboxamides for use in the treatment of multiple myeloma
HK1226643B (en) Quinoline carboxamides for use in the treatment of multiple myeloma
BR112017004947B1 (pt) Uso de um composto ou sal farmaceuticamente aceitável
EP4114368B1 (en) Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
HK1237658A1 (en) Quinoline carboxamides for use in the treatment of leukemia
HK1237658B (en) Quinoline carboxamides for use in the treatment of leukemia
TW202002970A (zh) 用於預防或治療癌症之組合物,其包含血管阻斷劑及紫杉烷化合物
JP2005041801A (ja) 細胞移植療法後の予後改善剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200902

EEER Examination request

Effective date: 20200902

EEER Examination request

Effective date: 20200902

EEER Examination request

Effective date: 20200902

EEER Examination request

Effective date: 20200902